期刊
PHARMACOGENETICS AND GENOMICS
卷 20, 期 9, 页码 569-572出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FPC.0b013e32833ca24b
关键词
antipsychotic; dopamine; DRD2; pharmacogenetics; weight gain
资金
- National Institute of Mental Health [K01 MH65580, R01 MH60004, P30 MH60575, K23 MH01760, P50 MH080173, K23 DA15541]
- General Clinical Research Center from the National Center for Research Resources [M01 RR18535]
- NARSAD
Many antipsychotic medications carry a substantial liability for weight gain, and one mechanism common to all antipsychotics is binding to the dopamine D-2 receptor. We therefore examined the relationship between -141C Ins/Del (rs1799732), a functional promoter region polymorphism in DRD2, and antipsychotic-induced weight gain in 58 first episode schizophrenia patients enrolled in a randomized trial of risperidone versus olanzapine. Carriers of the deletion allele (n = 29) were compared with Ins/Ins homozygotes (noncarriers, n = 29) in a mixed model encompassing 10 weight measurements over 16 weeks. Deletion allele carriers showed significantly more weight gain after 6 weeks of treatment regardless of assigned medication. Although deletion carriers were prescribed higher doses of olanzapine (but not risperidone), dose did not seem to account for the genotype effects on weight gain. Given earlier evidence that deletion carriers show reduced symptom response to medication, additional study of appropriate treatment options for these patients seems warranted. Pharmacogenetics and Genomics 20: 569-572 (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据